MAA Filing, Acceptance of ANDA Filing, Earnings Release, Study Results and Recognition - Research Reports on Regeneron, Mylan, Toll Brothers, 3M and Eaton

NEW YORK, September 8, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Mylan, Inc. (NASDAQ: MYL), Toll Brothers Inc. (NYSE: TOL), 3M Company (NYSE: MMM) and Eaton Corporation plc (NYSE: ETN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6281-100free.

--
Regeneron Pharmaceuticals, Inc. Research Reports
On September 4, 2014, Regeneron Pharmaceuticals, Inc. (Regeneron) announced that Bayer Yakuhin, Ltd, - Japanese subsidiary of Bayer HealthCare, has submitted a marketing authorization application (MAA) for EYLEA Injection for macular edema following branch retinal vein occlusion (BRVO) to the Japanese Ministry of Health, Labour and Welfare (MHLW). EYLEA is approved in Japan for curing patients with neovascular (wet), age-related macular degeneration (AMD), and macular edema secondary to central retinal vein occlusion (CRVO). According to the Company, MAA have been submitted in Japan for the treatment of choroidal neovascularization secondary to pathologic myopia (myopic CNV) and for the treatment of diabetic macular edema (DME). Regeneron and Bayer HealthCare have worked in collaboration on the global development of EYLEA and the former maintains exclusive rights to EYLEA in the US while Bayer HealthCare maintains the exclusive marketing rights outside the US. The full research reports on Regeneron are available to download free of charge at:

http://www.analystsreview.com/Sep-08-2014/REGN/report.pdf

--
Mylan, Inc. Research Reports
On August 28, 2014, Mylan, Inc. (Mylan) announced that the U.S. Food and Drug Administration (FDA) has accepted its abbreviated new drug application (ANDA) filing for a three times per week Glatiramer Acetate Injection 40 mg/mL. According to Mylan, the product is a generic version of Teva's Copaxone® 40 mg/mL, which is specified for the treatment of relapsing forms of multiple sclerosis (MS). According to the Company, it is one of first to file a comprehensive ANDA including Paragraph IV certification for the product. Mylan added that upon the Final FDA approval, it might get 180 days of marketing exclusivity for the product in the US. The full research reports on Mylan are available to download free of charge at:

http://www.analystsreview.com/Sep-08-2014/MYL/report.pdf

--
Toll Brothers Inc. Research Reports
On September 3, 2014, Toll Brothers Inc. (Toll Brothers) announced its Q3 FY 2014 and 9M FY 2014 financial results (period ended July 31, 2014). The revenues for the quarter came in at $1.1 billion, up 53.4% YoY and for 9M FY 2014 revenues were $2.6 billion, up 57.1% YoY. The average price of homes delivered in the quarter was $732,000, compared to $651,000 in Q3 FY 2014. On the other hand, in 9M FY 2014 net signed contracts came in at $2.9 billion, up 5% YoY. The net income for Q3 FY 2014 was $97.7 million, up 109.7% YoY with diluted EPS of $0.53 while for 9M FY 2014 net income was $208.5 million, up 175.4% YoY with diluted EPS of $1.13. Toll Brothers expects total home deliveries for FY 2014 to range from 5,300 to 5,500 at an average price of $710,000 million to $725,000 million per home, resulting in total home sales revenue between 3.76 billion and $3.99 billion. The full research reports on Toll Brothers are available to download free of charge at:

http://www.analystsreview.com/Sep-08-2014/TOL/report.pdf

--
3M Company Research Reports
On September 3, 2014, 3M Company reported the results of a new study commissioned by the Company on common airborne asthma and allergies, published in the August 2014 issue of the Journal of Asthma. According to the Company, using a high-efficiency air filter with a MERV rating of 12 or higher can effectively reduce indoor levels of common airborne asthma and allergy triggers. The study, designed and conducted by Environmental Health & Engineering, Inc., (EH&E) of Needham, Massachusetts EH&E professionals, assessed the efficiency of 6 kinds of residential air filters at capturing four types of microscopic particles found in indoor air of homes - which can distress indoor air quality and lead to cough, shortness of breath, wheezing, and other asthma symptoms. The results highlighted that Filtrete Healthy Living Ultra Allergen Reduction and Filtrete Healthy Living Ultimate Allergen Reduction 1-inch air filters captured over 50% of asthma and allergy triggers in a typical home. The full research reports on 3M are available to download free of charge at:

http://www.analystsreview.com/Sep-08-2014/MMM/report.pdf

--
Eaton Corporation plc Research Reports
On August 26, 2014, Eaton Corporation plc (Eaton) announced it was honored with the 2013 Quality Excellence Award from Hino Motors Canada, Ltd. and Hino Motors Manufacturing USA, Inc. for its durable and reasonable Synflex® air brake tubing products. Miguel Perez, fluid conveyance plant Manager, Eaton said, "Eaton's in-line dimension monitoring equipment ensures products are sized per the customer's specifications, and every length of tubing is tested to prevent leakage points. These standards helped Eaton achieve the quality performance benchmark of zero DPPM in 2013." The full research reports on Eaton are available to download free of charge at:

http://www.analystsreview.com/Sep-08-2014/ETN/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review